Enter your search terms:
logo
mobile logo
Top

Press Releases

02.08.2019
Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference

 

02.05.2019
Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation

 

01.31.2019
Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application

 

01.25.2019
Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen

 

01.03.2019
Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer

 

12.20.2018
Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters

 

12.18.2018
Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018

 

12.07.2018
Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

 

12.03.2018
Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy

 

11.29.2018
Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability

 

11.21.2018
Aquestive Provides Business Update Following Suboxone® Patent Ruling

 

11.16.2018
Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film

 

11.06.2018
Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

 

11.02.2018
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film

 

10.30.2018
Aquestive Therapeutics to Present at the Stifel 2018 Healthcare Conference

 

10.25.2018
Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018

 

10.25.2018
Aquestive Therapeutics Announces Completion of Diazepam Buccal Film Adult Epilepsy Monitoring Unit (EMU) Clinical Study with Positive Topline Results

 

09.11.2018
Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel

 

09.04.2018
Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™

 

08.31.2018
Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan™ (clobazam) Oral Film

 

08.15.2018
Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering

 

08.13.2018
Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors

 

07.31.2018
Aquestive Therapeutics to Present at the 2018 Wedbush Healthcare Conference

 

07.27.2018
Aquestive Therapeutics Announces Closing of Initial Public Offering

 

07.24.2018
Aquestive Therapeutics Announces Pricing of Initial Public Offering

 

07.16.2018
Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product

 

05.18.2018
Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals

 

05.02.2018
Aquestive Therapeutics Appoints Nancy Lurker to Board of Directors

 

01.31.2018
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS

 

01.18.2018
Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome

 

11.30.2017
MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio

 

Events

Presentations

Latest comments

Sorry, the comment form is closed at this time.